Highest-materiality recent filing
SI-BONE recalls 98 iFuse TORQ implants over sterility packaging failure
Voluntary recall of 98 iFuse TORQ implants from lots with tube packaging made May 4-15, 2026; 2 implanted, no infections reported.
SI-BONE Q2 revenue up 15.2% to $56.0M; raises FY 2026 revenue guidance to $231M-$233M
Net loss improved 33.6% to $4.1M ($0.09 loss per share) vs $6.2M loss a year ago.
SI-BONE extends HQ lease through Aug 2026; annual meeting passes all proposals
Lease term extended one month to Aug 31, 2026 with option for Sept 2026; base rent $43,696/month.
SI-BONE Q1 revenue $52.6M (+11%), net loss improves 33.8%; raises FY26 guidance
Worldwide revenue $52.6M (+11.2% YoY); US revenue $49.3M (+10.0%), international $3.3M (+33.9%).
Q4 2025 worldwide revenue $56.3M, up 15% YoY; FY2025 revenue $200.9M, up 20.2% YoY.
SI-BONE reports preliminary FY2025 revenue ~$200.8M, up ~20% YoY
Worldwide FY2025 revenue $200.8-$200.9M, ~20% growth; Q4 revenue $56.2-$56.3M, ~15% growth.
SI-BONE Q3 revenue $48.7M (+20.6% YoY), raises FY2025 guidance
Net loss improved to $4.6M ($0.11/share) from $6.6M ($0.16) a year ago.
SI-BONE Q2 revenue up 21.7% to $48.6M; raises FY guidance; announces CCO succession
Worldwide revenue $48.6M (+21.7% YoY); US revenue $46.4M (+22.8% YoY).
Directors elected: Timothy E. Davis Jr. (35.2M for), Laura A. Francis (35.5M for), Jeryl L. Hilleman (27.6M for, 8.6M withheld).
SI-BONE Q1 revenue up 25% to $47.3M, posts positive adjusted EBITDA, raises FY guidance
Worldwide revenue $47.3M, up 24.9% YoY; U.S. revenue $44.8M, up 26.6%.
SI-BONE Q4 2024 revenue $49M (+26% YoY); positive adjusted EBITDA; 2025 revenue guidance ~$194M
Q4 revenue $49.0M, up 26% YoY; U.S. revenue $46.9M (+28%); gross margin ~79%.
SI-BONE preliminary Q4 revenue ~$48.8-49.0M (+26% YoY); turns adjusted EBITDA profitable
Q4 worldwide revenue ~$48.8-49.0M (+26% YoY); US revenue ~$46.7-46.9M (+28%).
SI-BONE reports Q3 revenue $40.3M (+19% YoY); expects positive Adjusted EBITDA in Q4
Worldwide revenue $40.3M (+19% YoY); U.S. revenue $38.3M (+18% YoY).
SI-BONE Q2 revenue $40M (+20% YoY); raises 2024 guidance to $165-167M
Revenue $40.0M, up 20% YoY; U.S. revenue $37.8M (+21%). Net loss $8.9M ($0.22 loss per share) improved 20%.
SI-BONE extends corporate HQ lease through July 2026, base rent $43,696/month
Second Lease Amendment extends term 14 months to July 31, 2026 from June 1, 2025.
SI-BONE shareholders approve officer liability limitation; directors elected at annual meeting
Quorum of 89% (36.5M shares) present; all four proposals passed.
SI-BONE reports Q1 revenue $37.9M (+16% YoY); raises FY2024 guidance to $164-166M
Worldwide revenue $37.9M, up 16% YoY; U.S. revenue $35.4M, also up 16%.
Q4 worldwide revenue $38.9M (+22% YoY); US revenue $36.7M (+22%); gross margin 74% (down from 84%) due to $1.7M excess inventory reserve.
Q4 worldwide revenue $38.5-$38.7M, up ~21% YoY; US revenue $36.5-$36.6M (+22%).
SI-BONE reports Q3 2023 record revenue of $34.0M (+29% YoY); raises FY23 guidance to $136-137M
Q3 revenue $34.0M (+29% YoY); US revenue $32.3M (+31% YoY).
SI-BONE amends bylaws to align with SEC Universal Proxy Rules
Board adopted Second Amended and Restated Bylaws on September 19, 2023, effective immediately.
SI-BONE Q2 revenue $33.3M (+30% YoY); raises FY 2023 revenue guidance to $132-134M
Record worldwide revenue $33.3M (+30% YoY); U.S. revenue $31.2M (+31% YoY).
Directors Dunn, Freund, and Hinckley elected with approximately 79%, 80%, and 81% of votes cast, respectively.
SI-BONE announces public offering of 3.78M shares at $22.00 per share
Offering of 3,775,000 shares at $22.00 each; 3,502,247 from SI-BONE and 272,753 from selling stockholder.
SI-BONE Q1 revenue $32.7M (+46% YoY), raises FY2023 guidance to $128-131M
Record worldwide revenue $32.7M (+46% YoY); US revenue $30.5M (+50% YoY).
SI-BONE Q4 revenue up 27% to $32M; issues 2023 guidance of $124-127M
Q4 worldwide revenue $32.0M (+27% YoY); full year $106.4M (+18% YoY).
SI-BONE reports preliminary Q4 revenue ~$31.8M (+26% YoY) and refinances debt with $51M SVB facility
Q4 2022 preliminary revenue $31.7-31.9M, up ~26% YoY; FY 2022 revenue $106.1-106.3M, up ~18%.
SI-BONE posts Q3 2022 record revenue of $26.4M, up 19% YoY; guides FY22 revenue $104-105M
Worldwide revenue $26.4M (+19% YoY); U.S. revenue $24.6M (+21% YoY).
SI-BONE Q2 revenue $25.6M (+15% YoY); net loss $18.5M ($0.54/share)
Record worldwide revenue $25.6M, up 15% YoY; U.S. revenue $23.8M, up 18% YoY.
SI-BONE shareholders elect all three director nominees at 2022 annual meeting
Directors Davis, Francis, and Hilleman elected with ~22.3M votes each; 2.6M broker non-votes.
SI-BONE Q1 revenue $22.4M (+10% YoY); net loss $17.4M; reaffirms FY2022 guidance
Worldwide revenue $22.4M, up 10% YoY; U.S. revenue $20.4M (+9%), international $2.1M (+24%.
SI-BONE reports Q4 2021 revenue $25.2M (+14% YoY); net loss $0.43/share; FY2022 guidance $106-108M
Q4 2021 revenue $25.2M, up 14% YoY; full-year 2021 revenue $90.2M, up 23% YoY.
SI-BONE preliminary Q4 revenue $24.9-25.2M (+13-14% YoY); FY2021 revenue $89.8-90.1M (+22-23%)
Preliminary Q4 2021 revenue $24.9-25.2M, up 13-14% YoY; U.S. revenue $23.1-23.3M (+12-13%).
SI-BONE Q3 record revenue $22.3M (+9% YoY); net loss $15.9M; FY21 guidance $89-90M
Q3 worldwide revenue $22.3M, up 9% YoY; U.S. revenue $20.4M (+8%), international $1.9M (+31%).
SI-BONE enters $35M SVB term loan, repays $41.7M Solar Capital facility
$35M term loan from Silicon Valley Bank at greater of 5.75% or prime+2.5%; matures Aug 2025 or Aug 2026 if milestone met.
SI-BONE posts record Q2 revenue of $22.2M, gets exclusive Anthem coverage
Record Q2 worldwide revenue $22.2M (+58% YoY); U.S. revenue $20.2M (+53%).
On August 4, 2024, the Company’s board of directors (“Board”) elected Daniel Wolf to serve as a director of the Company effective August 5, 2024, until his successor is elected and qualified, or sooner in the event of his death, resignation or removal.
Max materiality 0.85 · Median 0.70 · Most common event earnings